Myovant Sciences Announces Priority Review and FDA Acceptance of New Drug Application for Once-Daily, Oral Relugolix for Advanced Prostate Cancer

On June 22, 2020 Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, reported that its New Drug Application (NDA) for once-daily, oral relugolix (120 mg) for the treatment of men with advanced prostate cancer has been accepted for Priority Review by the U.S. Food and Drug Administration (FDA) (Press release, Myovant Sciences, JUN 22, 2020, https://investors.myovant.com/news-releases/news-release-details/myovant-sciences-announces-priority-review-and-fda-acceptance [SID1234561327]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are delighted that the FDA has accepted for Priority Review our New Drug Application for relugolix, bringing us one step closer to providing a one pill, once a day potential new treatment option to men with advanced prostate cancer," said Lynn Seely, M.D., chief executive officer of Myovant Sciences. "As recently published in the New England Journal of Medicine, relugolix demonstrated superior efficacy and a 54% lower risk of major adverse cardiovascular events compared to the current standard of care, leuprolide acetate injections, in the Phase 3 HERO study."

The FDA grants Priority Review to applications for potential therapies that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications. The FDA has set a target action date of December 20, 2020 under the Prescription Drug User Fee Act (PDUFA). In its acceptance letter, the FDA also stated that it is currently not planning to hold an advisory committee meeting for this application. If approved, relugolix would be the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist treatment for men with advanced prostate cancer.

In May 2020, Myovant submitted a separate NDA for once-daily, oral relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) for women with heavy menstrual bleeding associated with uterine fibroids. A Marketing Authorization Application for relugolix combination tablet in women with moderate to severe symptoms associated with uterine fibroids is also under review by the European Medicines Agency.

About the Phase 3 HERO Program in Advanced Prostate Cancer
Myovant’s Phase 3 clinical program for advanced prostate cancer consisted of a randomized, open-label, parallel-group, multinational clinical study designed to evaluate the safety and efficacy of relugolix in over 900 men with androgen-sensitive advanced prostate cancer who required at least one year of continuous androgen deprivation therapy. Men were randomized 2:1 to receive a single loading dose of relugolix 360 mg followed by relugolix 120 mg once daily, or to treatment with leuprolide acetate 3-month depot injection, respectively.

Relugolix met the primary efficacy endpoint, with 96.7% of men treated with relugolix achieving sustained testosterone suppression to castrate levels (< 50 ng/dL) through 48 weeks versus 88.8% of men treated with leuprolide acetate. Relugolix also met all six key secondary endpoints, demonstrating superiority to leuprolide acetate in rapid and profound suppression of testosterone and PSA response, in addition to improved testosterone recovery after discontinuation of treatment. Men in the relugolix group had a 54% lower risk of major adverse cardiovascular events (MACE) compared to men in the leuprolide acetate group (2.9% vs. 6.2%, respectively). In men with a reported history of MACE, the relugolix group had 80% fewer MACE events reported compared to the leuprolide acetate group (3.6% vs. 17.8%, respectively). The overall incidence of adverse events in the relugolix and leuprolide acetate groups was comparable (92.9% vs. 93.5%, respectively).

Data from an additional key secondary endpoint, castration resistance-free survival, are expected in the third quarter of 2020.

About Prostate Cancer
Prostate cancer is the second most prevalent form of cancer in men and the second leading cause of death due to cancer in men in the U.S. Cardiovascular mortality is the leading cause of death in men with prostate cancer and accounts for 34% of deaths in men with prostate cancer in the U.S. More than three million men in the U.S. are currently living with prostate cancer, and approximately 190,000 men are estimated to be newly diagnosed in 2020. Advanced prostate cancer is prostate cancer that has spread or come back after treatment and may include men with biochemical recurrence (rising PSA in the absence of metastatic disease on imaging), locally advanced disease, or metastatic disease. Front-line medical therapy for advanced prostate cancer typically involves androgen deprivation therapy, which reduces testosterone to very low levels, commonly referred to as castrate levels. GnRH receptor agonists, such as leuprolide acetate, are depot injections and the current standard of care for androgen deprivation therapy. However, GnRH receptor agonists may be associated with mechanism-of-action limitations, including the potentially detrimental initial surge in testosterone levels that can exacerbate clinical symptoms, which is known as clinical or hormonal flare, and delayed testosterone recovery after the drug is discontinued. Approximately 210,000 men are treated with androgen deprivation therapy with a GnRH agonist or antagonist each year.

About Relugolix
Relugolix is a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist that reduces production of testicular testosterone, a hormone known to stimulate the growth of prostate cancer, and ovarian estradiol, a hormone known to stimulate the growth of uterine fibroids and endometriosis. Myovant is developing relugolix as a monotherapy tablet (120 mg once daily) for men with advanced prostate cancer. Myovant is also developing a relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) for women with uterine fibroids and for women with endometriosis.

TAZVERIK™ (tazemetostat) Now Approved for the Treatment of Relapsed/Refractory Follicular Lymphoma, Available from Onco360

On June 22, 2002 Onco360, the nation’s largest independent Oncology Pharmacy, reported that it has been selected by Epizyme to be the specialty pharmacy partner for TAZVERIK (Tazemetostat), a new oral treatment for adult with relapsed/refractory follicular lymphoma whose tumors are positive for an EZH2-mutation as detected by an U.S. Food and Drug Administration (FDA)-approved test and who have received at least two prior systemic therapies or for adult patients with relapsed/refractory follicular lymphoma who have no satisfactory alternative treatment options (Press release, Onco360, JUN 22, 2020, View Source [SID1234561343]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The approval of TAZVERIK as a treatment option for patients with relapsed/refractory follicular lymphoma is an important advancement in fighting this devastating disease," said Paul Jardina, President and CEO, Onco360. "As a specialty oncology pharmacy, we are committed to improving the lives of cancer patients suffering from follicular lymphoma."

Follicular lymphoma is the second-most common type of non-Hodgkin lymphoma and is considered to be indolent, yet incurable. According to the National Comprehensive Cancer Network Guidelines for B-Cell Lymphomas, approximately 12,600 patients are diagnosed with follicular lymphoma on an annual basis. When considering all stages of the disease, follicular lymphoma has a five-year overall survival of 89%. Approximately 30% of follicular lymphoma patients are found to have EZH2-mutations.

TAZVERIK is manufactured by Epizyme, a global, commercial-stage, research-based biotechnology company, and was previously approved by the FDA in January 2020 for the treatment of adult and pediatric patients (aged 16 years and older) with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. The FDA’s approval of TAZVERIK for relapsed/refractory follicular lymphoma is based on the results of two open-label, single-arm cohorts of the Phase I/II E7438-G000-101 clinical trial (NCT01897571) which demonstrated a 69% overall response rate in EZH2-mutant relapsed/refractory follicular lymphoma patients who received at least two prior lines of systemic therapy and a 34% overall response rate in EZH2-wild-type relapsed/refractory follicular lymphoma patients who received at least two prior lines of systemic therapy. For full prescribing information, visit TAZVERIK.com.

ABM Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of ABM-1310 in the USA

On June 22, 2020 ABM Therapeutics, a clinical-stage biopharmaceutical company developing a new generation of BRAF inhibitor, reported that the first cancer patient has been successfully enrolled and dosed with ABM-1310 in the Phase 1 clinical trial in the USA (Press release, ABM Therapeutics, JUN 22, 2020, View Source [SID1234561359]). ABM-1310, the company’s lead candidate, demonstrated superior properties in pre-clinical animal models, is a highly selective, highly water-soluble, orally active, and brain-penetrant small molecule BRAF inhibitor.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dosing the first patient in the USA represents another important milestone, both for ABM-1310 program and for patients. "We are so grateful to patients and their families, investigators and clinical study sites for their support on the study," Dr. Chen Chen, founder and CEO of ABM Therapeutics said. "Many cancer patients are affected by brain metastases, but current treatment options are limited. ABM-1310 significantly prolonged median survival time of brain metastases in preclinical models and is expected to be a new generation of BRAF inhibitors for the treatment of various malignant tumors and brain metastases. We have been at full speed conducting clinical development of ABM-1310 in the USA and hope to bring the potential therapeutic benefits to patients as soon as possible."

ABM-1310 phase 1 trial is a multi-center, open-label study to test the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of ABM-1310 in patients with BRAF mutant advanced solid tumor and BRAF mutant patients with brain metastases. The goal of the study is to determine the optimal dose for phase 1b/2 studies.

"We have designed our Phase 1 trial to move efficiently through dose escalation and to increase the chance of seeing early signs of clinical activity by focusing on the BRAF mutant patient population. We look forward to producing important early clinical data to guide our future clinical development," said Dr. Charles Zhao, Chief Medical Officer of ABM Therapeutics. "Based on the preclinical potency of ABM-1310, we believe it could provide a profound benefit for patients in urgent need of new therapies as both a single agent and in combination with other therapies."

As a clinical-stage biotechnology company, ABM Therapeutics has broad and robust proprietary pipeline to construct a brain medicine R&D platform. It will continue to focus on the small molecule research and development of novel drugs for the treatment of cancer, with an emphasis on blood–brain barrier (BBB) penetration and brain metastasis. We look forward to working with international pharmaceutical companies and biotech companies from multiple perspectives to make our drug to benefit more patients in the world.

Roche, BioNTech post ‘low’ response rate in cancer vaccine trial

On June 22, 2020 BioNTech reported that A phase 1b trial of a personalized cancer vaccine in development at Roche has chalked up a "low" response rate (Press release, BioNTech, JUN 22, 2020, View Source [SID1234561516]). Nine of the 108 evaluable solid tumor patients responded when given the vaccine in combination with Tecentriq, although researchers pointed to immune response results to support continued study in other populations.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Roche’s Genentech paid BioNTech $310 million in upfront and near-term milestones in 2016 to gain access to mRNA-based personalized cancer vaccines. The collaboration gave rise to RO7198457, a drug that targets up to 20 tumor-associated antigens (TAAs) expressed by a patient’s cancer. By giving patients mRNA corresponding to TAAs, Roche and BioNTech hope to rally cytotoxic T-lymphocyte and memory T-cell-dependent immune responses against tumors.

Researchers are using this week’s virtual American Association for Cancer Research (AACR) (Free AACR Whitepaper) event to share an early look at whether RO7198457, also known as BNT122, works as hoped. The results contain plenty of ammunition for anyone who is skeptical about the likelihood of Roche and BioNTech ending the long losing streak of cancer vaccines.

How the fast-changing R&D pipeline is amplifying the importance of adaptable CROs
The story of CMIC’s rise from being a startup in a one-room apartment to a multinational leader is defined by an ability and readiness to foresee the changing needs of biopharma companies and adapt accordingly. With pipelines primed to continue evolving in the coming years, that adaptable approach is now more important than ever.
DOWNLOAD NOW
Evaluations of 108 patients who received RO7198457 and checkpoint inhibitor Tecentriq identified nine responses, including one complete response. The figures translate into a response rate of 8%. It is unclear whether those subjects would have responded to Tecentriq given as a monotherapy. A smaller assessment of RO7198457 as a monotherapy linked the cancer vaccine to a 4% response rate.

Juanita Lopez, Ph.D., consultant medical oncologist at The Royal Marsden and co-author of the RO7198457 abstract, said the "clinical response rate overall was low" in a statement about the trial. Despite that, Lopez sees positives in the results, noting that "we were able to generate tumor-specific immune responses in the majority of evaluable patients."

An analysis of peripheral blood taken from 49 patients found evidence of neoantigen-specific T cell responses in 77% of samples. Viewed alongside the efficacy data, the analysis suggests RO7198457 reliably elicits specific immune responses that rarely translate into reductions in tumor size.

Lopez thinks the health status of participants at baseline may explain why immune activity is failing to translate into partial and complete responses. Participants in the combination trial had received a median of three prior therapies. Almost 40% of subjects had previously received immunotherapy. It is unclear if any of the nine patients who responded to the combination had previously received an immunotherapy.

The debate over whether RO7198457 is a dud or a good drug given to the wrong patients will remain inconclusive until data from other populations are available. Roche and BioNTech began gathering such data last year by initiating a phase 2 trial of RO7198457 in combination with Merck’s Keytruda. The trial is randomizing previously untreated advanced melanoma patients to receive Keytruda as a single agent or in combination with RO7198457.

That design positions the trial to clear up questions raised by the Tecentriq combination study about what RO7198457 contributes to checkpoint inhibitor cocktails and whether it works better earlier in the treatment pathway. Lopez said work to assess RO7198457 in post-surgery early-stage non-small cell lung cancer patients is also underway.

AIMM Therapeutics presents new preclinical data at AACR 2020

On June 22, 2020 AIMM, a privately-held biopharmaceutical company, reported it has presented preclinical data at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2020 Virtual Annual Meeting from its antibody programs in oncology using a rich pipeline of tumor- specific antibodies from cured cancer patients (Press release, AIMM Therapeutics, JUN 22, 2020, View Source [SID1234561293]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Recognizing that cured cancer patients have benefited, directly or indirectly, from a robust and specific antibody response, AIMM has set out to select those functional antibodies as a starting point for its drug development programs," said John Womelsdorf, Ph.D., chief executive officer of AIMM Therapeutics. "AIMM is perfectly positioned to advance this approach; firstly, through our ability to interrogate the entire B cell repertoire of the surviving patient and identify novel targets and anti-cancer antibodies using our AIMSelect platform. And, secondly, we are able to potentiate these antibodies for use as therapies through our AIMProve platform to leverage the unique biology that was underlying the original donor’s successful clinical response."

AIMM has a pipeline of multiple drug candidates that bind to novel cancer targets and epitopes. The company’s lead asset, AT1412, is a CD9-targeted antibody derived from a stage 4 melanoma patient with brain metastasis who was successfully treated with autologous T-cell based immunotherapy and is still tumor-free after 13 years despite having an aggressive cancer. AT1412 is going through the last stages of preclinical development for B-cell lymphoblastic leukemia/lymphoma (B-ALL) and CD9+ solid tumors, such as melanoma, gastric, breast, and esophageal cancers. Preclinical data from studies of AT1412 in B-ALL and melanoma tumor models show monotherapy treatment induced full tumor rejection that in the case of melanoma can be further sustained in combination with nivolumab. Two posters presented at AACR (Free AACR Whitepaper) demonstrate the potential for AT1412 to be a potent antibody capable of inducing cell death and facilitating the trafficking of immune cells into the tumor microenvironment.

Additionally, several antibody candidates, such as CD3-bispecific/ADC/CAR-T assets, are in lead optimization and could provide for multiple non-dilutive partnering opportunities and co-development collaborations. AT1413, isolated from an M5 acute myeloid leukemia patient that underwent allograft stem cell transplantation, has the potential to be formatted into a CD3-bispecific, ADC or CAR-T. Another poster presented at AACR (Free AACR Whitepaper) describes two different bispecific T-cell engaging forms of AT1413 that induce strong anti-tumor cytotoxic activities in AML and solid tumors like melanoma and breast carcinoma. A fourth poster presented at the AACR (Free AACR Whitepaper) annual meeting reviews AT1636, an antibody targeting a cancer- specific glyco-modified antigen, which was retrieved from a patient with Lynch syndrome.

Hans van Eenennaam, Ph.D., who joined AIMM Therapeutics in 2019 as its chief scientific officer and is credited as a co-inventor of pembrolizumab, added, "Using patient-derived antibodies as therapeutics represents an exciting approach to drug development because they are unlocking novel targets and mechanisms of action. As exemplified by our AT1412 (anti-CD9 antibody), we have identified that this patient-derived antibody induces antibody-mediated tumor kill and promotes immune cell penetration into the tumor. Our technologies were initially developed and validated for applications in infectious disease, resulting in the out licensing of a product candidate for respiratory syncytial virus to MedImmune that is now in Phase 3 development. Following years of groundbreaking experience in the field led by my predecessor and founder of the company Hergen Spits, professor at the Academic Medical Center in Amsterdam, we are now applying our evolved and highly selective antibody technologies to treat cancer. Our unique and proprietary technology allows us to interrogate every memory B-cell in both human blood and tumors for anti-cancer reactivity. Together with our rich tradition of cutting-edge immunology, we are uniquely positioned to identify targets on both hematological and solid tumors that have not been previously identified before."

AACR Presentations on June 22, 2020
Poster 531, Session: Antibody Technologies
AT1412, a patient-derived antibody in development for the treatment of cd9-positive precursor b-acute lymphoblastic leukemia

Poster 532, Session: Antibody Technologies
A patient-derived anti-CD9 antibody induces tumor rejection and synergistically enhances anti-PD1 activity

Poster 542, Session: Antibody Technologies
T-cell engager bispecific formats of an AML patient-derived antibody targeting a unique sialylated CD43 epitope induce kill of melanoma cells in vitro and in vivo

Poster 5163, Session: Antibody Technologies
A colon cancer survivor-derived antibody recognizes a previously unidentified truncated, O-mannosylated 70kDa variant of E-cadherin